Zenith Recruiting Metastatic Prostate Cancer Patients for New Clinical Trial

Zenith Recruiting Metastatic Prostate Cancer Patients for New Clinical Trial
Zenith Epigenetics has started a Phase 1b clinical trial to assess the safety and tolerability of its orally administered BET inhibitor ZEN-3694 in combination with Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after first-line androgen-deprivation therapy. Current standard of care treatment for prostate cancer patients consists of androgen deprivation therapies such as Xtandi, which blocks the androgen receptor, or Zitiga (abiraterone), which impairs the synthesis of androgens. Although most patients respond to these castration therapies, nearly all patients eventually become resistant to them. Castration-resistant prostate cancer patients have no effective therapies to treat their dis
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *